Binosto is owned by Ascend Theraps Us.
Binosto contains Alendronate Sodium.
Binosto has a total of 3 drug patents out of which 0 drug patents have expired.
Binosto was authorised for market use on 12 March, 2012.
Binosto is available in tablet, effervescent;oral dosage forms.
The generics of Binosto are possible to be released after 05 December, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7964212||ASCEND THERAPS US||Effervescent compositions comprising phosphonates and methods related thereto|| |
(a month from now)
|US7488496||ASCEND THERAPS US||Effervescent compositions comprising bisphosphonates and methods related thereto|| |
(6 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9592195||ASCEND THERAPS US||Stable effervescent bisphosphonate formulations with rapid solubilization characteristics|| |
(8 years from now)
Market Authorisation Date: 12 March, 2012
Dosage: TABLET, EFFERVESCENT;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic